Galderma Presented Three-Year Data for Nemluvio
The ARCADIA study demonstrated long-term eczema symptom relief and quality of life improvements in clinical trials.
Updated on Sept. 30, 2026 in Asthma
Live Poll
Do you trust the long-term safety data provided by pharmaceutical companies for new skin medications?
Galderma has released three-year findings from the ARCADIA study, showing consistent efficacy for its drug Nemluvio in treating eczema. Patients aged 12 and older reported sustained improvements in skin clarity and itch relief over 152 weeks.
Why it matters
These results validate the long-term safety and durability of Nemluvio, a treatment that targets IL-31 signaling to manage chronic skin inflammation. The data supports the drug's ongoing clinical utility across more than 40 countries where it has received regulatory approval.
The 152-week ARCADIA study showed up to 92% of patients achieved quality of life improvements, with 67% attaining clear or almost clear skin. The drug, which inhibits IL-31 signaling, maintains a consistent safety profile after three years.
The players
Galderma
Galderma is a Switzerland-based dermatological pharmaceutical company that focuses on developing treatments for various skin conditions.
EADV Congress
The European Academy of Dermatology and Venereology Congress is a major annual medical conference that showcases clinical breakthroughs in skin health.
The details
Researchers utilized an open-label long-term extension design to track patient outcomes for 152 weeks. The study focused on individuals aged 12 and older to evaluate the sustained impact of the medication on eczema severity.
Timeline
Galderma obtained exclusive rights to nemolizumab in 2016.
Clinical trial data was presented on October 1, 2026.
The Big Picture
The presentation at the EADV Congress follows a pattern set by EADV research initiatives to highlight long-term dermatological drug efficacy. This study underscores the shift toward assessing chronic treatment durability rather than just short-term outcomes in dermatological medicine.
The results provide long-term assurance for patients currently using or considering Nemluvio to manage eczema and itch symptoms. Individuals can discuss these three-year outcomes with their healthcare providers to better understand the durability of their treatment plan.
The takeaway
The study confirms that targeting IL-31 signaling can provide lasting relief for chronic skin conditions over an extended period. Patients should focus on long-term consistency when managing skin severity rather than expecting immediate, permanent results.
Further reading
For more information on current treatment standards, visit the Asthma section.
Live Poll
Do you trust the long-term safety data provided by pharmaceutical companies for new skin medications?
